Education
About Us
Working with TipRanks
Follow Us
Moolec Science (MLEC)
NASDAQ:MLEC
Top Page
Moolec Science
(NASDAQ:MLEC)
46Neutral
Moolec Science (MLEC) vs. S&P 500 (SPY)
Market Cap
$30.06M
Dividend YieldN/A
Average Volume (3M)107.67K
Price to Earnings (P/E)―
Beta (1Y)-0.30
Revenue Growth170.36%
EPS Growth-24.94%
CountryUS
Employees52
SectorHealthcare
Sector Strength58
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding40,126,840
10 Day Avg. Volume290,427
30 Day Avg. Volume107,665
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Moolec Science Business Overview & Revenue Model
Company DescriptionMoolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.
How the Company Makes MoneyMoolec Science makes money primarily through the commercialization of its molecular farming technology and the sale of its plant-based protein products. Key revenue streams include licensing agreements with food manufacturers and agricultural companies who utilize Moolec's technology to incorporate animal proteins into their product offerings. Additionally, Moolec may engage in direct sales of its protein products to food processing companies. Significant partnerships with industry leaders and research institutions further enhance the company's ability to generate income through collaborative development projects and joint ventures.
Moolec Science Financial Statement Overview
Summary
Moolec Science is experiencing rapid revenue growth, but profitability remains a concern with negative margins and increasing leverage. The balance sheet suggests rising financial risk due to higher debt levels. Cash flow challenges persist, with negative free and operating cash flows, indicating potential liquidity issues. The company needs to address profitability and cash flow management to improve financial stability.Income Statement
Moolec Science's income statement reveals a significant improvement in revenue, growing from $905,049 in 2023 to $5,625,124 in 2024, indicating strong revenue growth. However, the company remains unprofitable with a negative net income of $7,312,260 in 2024. Gross profit margin improved to 8.4%, but EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.45
Neutral
Balance Sheet
The balance sheet shows increased leverage with a debt-to-equity ratio of 2.15 in 2024, up from 0.26 in 2023. The equity ratio declined to 19.6%, suggesting higher financial risk. However, the company's total assets increased, indicating expansion. The negative return on equity of -107.3% highlights profitability issues.50
Neutral
Cash Flow
Cash flow analysis indicates a challenging cash position with negative operating and free cash flow in 2024. Free cash flow was -$9,486,551, worsening from -$7,690,539 in 2023, showing a negative growth trend. The operating cash flow to net income ratio is negative, highlighting cash flow management issues.40
Negative
| Breakdown | |||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|
| Income Statement | Total Revenue | ||
| 5.63M | 905.05K | 0.00 | 0.00 | Gross Profit |
| 472.58K | -143.31K | 0.00 | 0.00 | EBIT |
| -9.04M | -6.65M | -3.65M | -13.80K | EBITDA |
| -6.16M | -51.74M | -3.65M | -13.80K | Net Income Common Stockholders |
| -7.31M | -51.79M | -4.53M | -13.80K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
| 5.39M | 2.83M | 1.08M | 980.53K | Total Assets |
| 34.79M | 24.05M | 5.69M | 5.88M | Total Debt |
| 14.68M | 2.65M | 125.00K | 295.00K | Net Debt |
| 9.29M | 117.62K | -956.81K | -685.53K | Total Liabilities |
| 27.97M | 13.95M | 4.09M | 587.66K | Stockholders Equity |
| 6.82M | 10.11M | 1.60M | 5.29M |
| Cash Flow | Free Cash Flow | ||
| -9.49M | -7.69M | -1.89M | -8.80K | Operating Cash Flow |
| -9.33M | -7.51M | -1.89M | -8.80K | Investing Cash Flow |
| 134.87K | -2.34M | -138.00M | 0.00 | Financing Cash Flow |
| 11.71M | 11.28M | 2.00M | 14.49K |
Moolec Science Technical Analysis
Positive
0.75
Price Trends
0.71
Positive
0.75
Positive
0.82
Negative
Market Momentum
<0.01
Negative
58.10
Neutral
88.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLEC, the sentiment is Positive. The current price of 0.75 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.71, and below the 200-day MA of 0.82, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.10 is Neutral, neither overbought nor oversold. The STOCH value of 88.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLEC.
Moolec Science Risk Analysis
Moolec Science disclosed 52 risk factors in its most recent earnings report. Moolec Science reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Moolec Science Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% | |
46 Neutral | $30.06M | ― | -174.68% | ― | 170.36% | -24.94% | |
46 Neutral | $41.63M | ― | -22.89% | ― | ― | 75.74% | |
41 Neutral | $24.63M | ― | -79.46% | ― | -95.30% | -135.89% | |
39 Underperform | $29.43M | ― | -93.54% | ― | ― | 38.65% | |
39 Underperform | $28.45M | ― | -88.91% | ― | ― | 30.37% | |
30 Underperform | $34.24M | ― | -415.84% | ― | -74.60% | ― |
* Healthcare Sector Average
Performance Comparison
MLEC
Moolec Science
0.75
-0.64
-46.04%
CLGN
Collplant Holdings
2.15
-3.70
-63.25%
GRCE
Grace Therapeutics
3.04
0.09
3.05%
ALLK
Allakos
0.33
-0.84
-71.79%
ALXO
ALX Oncology Holdings
0.53
-15.25
-96.64%
ALGS
Aligos Therapeutics
5.60
-14.65
-72.35%
Moolec Science Earnings Call Summary
Earnings Call Date:Mar 12, 2025
(Q4-2024)
| % Change Since: -20.21%|
Next Earnings Date:May 28, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant achievements in revenue growth, regulatory approvals, and strategic partnerships. However, there are challenges with increased operating expenses and cash utilization.Q4-2024 Updates
Positive Updates
Significant Revenue Increase
Normalized revenues increased from approximately $1 million in 2023 to $5.8 million in 2024, due to the consolidation of the soy product ingredient business.
Regulatory Approval Breakthrough
Moolec received the first-ever USDA approval for Piggy Sooy, making it the first company in the industry to achieve such a regulatory milestone.
Successful R&D and Commercialization Efforts
Moolec has successfully set up a fully owned plant molecule and biology lab, achieved significant results in transgenic events, and is preparing for the commercialization of Glaso products.
Strategic Partnerships and Growth Plans
Moolec signed an offtake agreement with a major global CPG company for Glaso and an R&D collaboration with Bunge to develop safflower varieties.
Negative Updates
Increased Operating Expenses
SG&A and R&D expenses increased by $3.1 million, mainly due to non-cash items and the consolidation of the soy ingredient business.
Cash Utilization Rise
Cash used in operating activities increased by $1.8 million from $7.5 million in 2023 to $9.3 million in 2024.
Company Guidance
During Moolec Science's fourth quarter and full fiscal year 2024 conference call, the company shared key financial metrics and future guidance. The fiscal year 2024 saw a significant increase in normalized revenues, jumping from approximately $1 million in 2023 to $5.8 million in 2024, largely due to the consolidation of the soy product ingredient business. The cost of sales increased correspondingly, from close to $1 million in 2023 to $4.5 million in 2024, resulting in an annual gross margin that remains undisclosed. Expenses, including SG&A and R&D, rose by $3.1 million, reaching $9.3 million, driven by non-cash items and the soy ingredient business consolidation. Cash utilization in operating activities increased from $7.5 million in 2023 to $9.3 million in 2024, with a significant $4 million reduction in accounts payable. As of Q4 2024, the cash position stood at approximately $5.4 million, bolstered by the strategic purchase of 15,000 tons of HB4 soybean. Looking ahead, Moolec anticipates fiscal year 2025 to be pivotal, with the commercialization of new science-based ingredients like Glaso, supported by a three-year contract with a major CPG company, and efforts to enhance operational efficiencies and regulatory progress.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.